Cancer vaccines: current status and future directions
Top Cited Papers
Open Access
- 17 February 2025
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 18 (1) , 1-30
Abstract
Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune checkpoint inhibitors and adoptive cellular therapy, cancer vaccines have garnered significant interest, but their clinical success remains modest. Benefiting from advancements in technology, many meticulously designed cancer vaccines have shown promise, warranting further investigations to reach their full potential. Cancer vaccines hold unique benefits, particularly for patients resistant to other therapies, and they offer the ability to initiate broad and durable T cell responses. In this review, we highlight the antigen selection for cancer vaccines, introduce the immune responses induced by vaccines, and propose strategies to enhance vaccine immunogenicity. Furthermore, we summarize key features and notable clinical advances of various vaccine platforms. Lastly, we delve into the mechanisms of tumor resistance and explore the potential benefits of combining cancer vaccines with standard treatments and other immunomodulatory approaches to improve vaccine efficacy.Keywords
Funding Information
- The National Science Fund for Excellent Young Scholars (No. 32122052)
This publication has 312 references indexed in Scilit:
- rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic CellsAdvanced Science, 2024
- Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast CancerJAMA Oncology, 2023
- Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent GlioblastomaJAMA Oncology, 2022
- Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate CancerJAMA Oncology, 2022
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related CancerJAMA Oncology, 2019
- Effect of Modified Vaccinia Ankara–5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal CancerJAMA Oncology, 2017
- Tumor‐derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitroHepatology, 2016
- Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T‐cell activationEuropean Journal of Immunology, 2013
- Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentationEuropean Journal of Immunology, 2008